Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer

Pharmacological Reviews

Volumn 55, Issue 1, 2003, Pages 57-103

  Danesi, Romano ^a   De Braud, Filippo ^b   Fogli, Stefano ^a   De Pas, Tommaso Martino ^b   Di Paolo, Antonello ^a   Curigliano, Giuseppe ^b   Del Tacca, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE 2; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIPODOPHYLLOTOXIN DERIVATIVE; ERLOTINIB; ETOPOSIDE; FOLIC ACID DERIVATIVE; FRAGILE HISTIDINE TRIAD PROTEIN; FTI 2148; FTI 2153; GEFITINIB; GEMCITABINE; HISTONE; IFOSFAMIDE; LONAFARNIB; MULTIDRUG RESISTANCE PROTEIN; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; PROTEIN BCL 2; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P16; PROTEIN P53; PROTEOME; RECEPTOR BLOCKING AGENT; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DEACETYLATION; DNA DETERMINATION; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; FEBRILE NEUTROPENIA; GENE AMPLIFICATION; GENE FUNCTION; GENE LOSS; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; GENOME ANALYSIS; HETEROZYGOSITY LOSS; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MALIGNANT TRANSFORMATION; MEDICAL DECISION MAKING; META ANALYSIS; METHYLATION; MICROSATELLITE INSTABILITY; NEUROTOXICITY; NONHUMAN; ONCOGENE MYC; ONCOGENE RAS; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DETERMINATION; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; RASH; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TECHNIQUE; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 0037371443     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: 10.1124/pr.55.1.4     Document Type: Review

References (327)

1. Adachi J, Shiseki M, Okazaki T, Ishimaru G, Noguchi M, Hirohashi S, and Yokota J (1995) Microsatellite instability in primary and metastatic lung carcinomas. Genes Chrom Cancer 14:301-306.
2. Adams DJ and Knick VC (1995) P-glycoprotein mediated resistance to 5′-noranhydro-vinblastine (Navelbine). Invest New Drugs 13:13-21.
3. Adjei AA, Davis JN, Bruzek LM, Erlichman C, and Kaufmann SH (2001) Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin Cancer Res 7:1438-1445.
4. Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, Esteller M, Herman JG, Wu L, Decker PA, Jen J, and Sidransky D (1999) Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 91:299-301.
5. Alberola V, Camps C, Provencia M, Isla D, Rosell R, Vadell C, Bover I, Ruiz Casado A, Azagra P, Jiménez U, González-Larriba J, Cardenal F, Artal A, Carrato A, Morales S and Sanchez J (2001) Cisplatin/gemcitabine (CG) vs. cisplatin/gemcitabine/vinorelbine (CGV) vs. sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (GV/IV) in advanced non-small cell lung cancer (NSCLC): results of a Spanish Lung Cancer Group phase III trial (GEPC/98-02) (Abstract 1229). Proc Am Soc Clin Oncol 20:308a.
6. Alvarez M, Robey R, Sandor V, Nishiyama K, Matsumoto Y, Paull K, Bates S, and Fojo T (1998) Using the National Cancer Institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles. Mol Pharmacol 54:802-814.
7. Amati B, Frank SR, Donjerkovic D, and Taubert S (2001) Function of the c-Myc oncoprotein in chromatin remodeling and transcription. Biochim Biophys Acta 1471:M135-145.
8. Anderson L and Seilhamer J (1997) A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 18:533-537.
9. Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, Brouchet L, Quoix E, Westeel V, and Le Chevalier T (2000) Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 18:2981-2989.
10. Aoe K, Kiura K, Ueoka H, Tabata M, Matsumura T, Chikamori M, Matsushita A, Kohara H, and Harada M (1999) Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res 19:291-299.
11. Arbit E, Wronski M, Burt M, and Galicich JH (1995) The treatment of patients with recurrent brain metastases. A retrospective analysis of 109 patients with non-small cell lung cancer. Cancer 76:765-773.
12. Baumann M, Appold S, Petersen C, Zips D, and Herrmann T (2001) Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer. Lung Cancer 33 (Suppl 1):S35-S45.
13. Baylin SB and Herman JG (2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 16:168-174.
14. Baylin SB, Herman JG, Graff JR, Vertino PM, and Issa JP (1998) Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141-196.
15. Beausejour CM, Gagnon J, Primeau M, and Momparler RL (2002) Cytotoxic activity of 2′, 2′-difluorodeoxycytidine, 5-aza-2′-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene. Biochem Biophys Res Commun 293:1478-484.
16. Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson E, Baylin SB, and Herman JG (1998) Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 95:11891-11896.
17. Berger W, Elbling L, Hauptmann E, and Micksche M (1997) Expression of the multidrug resistance-associated protein (MRP) and chemoresistance of human non-small-cell lung cancer cells. Int J Cancer 73:84-93.
18. Berger W, Elbling L, and Micksche M (2000) Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-term exposure to antineoplastic drugs. Int J Cancer 88:293-300.
19. Bergman AM, Munch-Petersen B, Jensen PB, Sehested M, Veerman G, Voorn DA, Smid K, Pinedo HM, and Peters GJ (2001a) Collateral sensitivity to gemcitabine (2′, 2′-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines. Biochem Pharmacol 61:1401-1408.
20. Bergman AM, Pinedo HM, and Peters GJ (2001b) Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells. Eur J Pharmacol 416:19-24.
21. Black DM (1997) Tumour suppressor genes and inheritance of cancer, in Oncogenes and tumour suppressors (Peters G and Vousden KH eds) pp 293-313, IRL Press, Oxford.
22. Blay J, White TD, and Hoskin DW (1997) The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res 57:2602-2605.
23. Boldrini L, Calcinai A, Samaritani E, Pistolesi F, Mussi A, Lucchi M, Angeletti CA, Basolo F and Fontanini G (2000) Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer 83:480-486.
24. Bonnet RB, Bush D, Cheek GA, Slater JD, Panossian D, Franke C, and Slater JM (2001) Effects of proton and combined proton/photon beam radiation on pulmonary function in patients with resectable but medically inoperable non-small cell lung cancer. Chest 120:1803-1810.
25. Borner MM, Brousset P, Pfanner-Meyer B, Bacchi M, Vonlanthen S, Hotz MA, Altermatt HJ, Schlaifer D, Reed JC, and Betticher DC (1999) Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer 79:952-958.
26. Borst P, Evers R, Kool M, and Wijnholds J (1999) The multidrug resistance protein family. Biochim Biophys Acta 1461:347-357.
27. Boulay JL, Perruchoud AP, Reuter J, Bolliger C, Herrmann R, and Rochlitz C (2000) P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients. Cancer Gene Ther 7:1215-1219.
28. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Holscher AH, and Danenberg PV (2001) Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7:1850-1855.
29. Brattstrom D, Bergqvist M, Lamberg K, Kraaz W, Scheibenflug L, Gustafsson G, Inganas M, Wagenius G, and Brodin O (1998) Complete sequence of p53 gene in 20 patients with lung cancer: comparison with chemosensitivity and immunohistochemistry. Med Oncol 15:255-261.
30. Brennan J, O'Connor T, Makuch RW, Simmons AM, Russell E, Linnoila RI, Phelps RM, Gazdar AF, Ihde DC, and Johnson BE (1991) Myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Res 51:1708-1712.
31. Broermann P, Junker K, Brandt BH, Heinecke A, Freitag L, Klinke F, Berdel WE, and Thomas M (2002) Trimodality treatment in Stage III non-small cell lung carcinoma: prognostic impact of K-ras mutations after neoadjuvant therapy. Cancer 94:2055-2062.
32. Brognard J, Clark AS, Ni Y, and Dennis PA (2001) Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61:3986-3997.
33. Buccheri G and Ferrigno D (2001) Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancer. Lung Cancer 34:433-440.
34. Bunn PA Jr, Soriano A, Johnson G, and Heasley L (2000) New therapeutic strategies for lung cancer. Biology and molecular biology come of age. Chest 117:163S-168S.
35. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M and Minna JD (2001) RASSFIA in the 3p21.3 homozygous deletion region: epigenetic inactivation in lung and breast cancer and suppression of the malignant phenotype. J Natl Cancer Inst 93:691-699.
36. Büssow K, Konthur Z, Lueking A, Lehrach H, and Walter G (2001) Protein array technology - Potential use in Medical diagnostics. Am J Pharmacogenomics 1:37-43.
37. Chalfant CE, Rathman K, Pinkerman RL, Wood RE, Obeid LM, Ogretmen B, and Hannun YA (2002) De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. J Biol Chem 277:12587-12595.
38. Chen Z, Ke LD, Yan XH, and Adler-Storthz K (2000) Correlation of cisplatin sensitivity with differential alteration of EGFR expression in head and neck cancer cells. Anticancer Res 20:899-902.
39. Chizhikov V, Zborovskaya I, Laktionov K, Delektorskaya V, Polotskii B, Tatosyan A, and Gasparian A (2001) Two consistently deleted regions within chromosome 1p32-pter in human non-small cell lung cancer. Mol Carcinog 30:151-158.
40. Ciardiello F and Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958-2970.
41. Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, and Ackland SP (2002) Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapynaive patients with advanced non-small-cell lung cancer. Ann Oncol 13:737-741.
42. Contessa JN, Hampton J, Lammering G, Mikkelsen RB, Dent P, Valerie K, and Schmidt-Ullrich RK (2002) Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 21:4032-4041.
43. Cortes-Funes H (2002) New treatment approaches for lung cancer and impact on survival. Semin Oncol 29 (Suppl 8):26-29.
44. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK and Plass C (2000) Aberrant CpG-island methylation has non-random and tumor-type-specific patterns. Nat Genet 24:132-138.
45. Cox G, Vyberg M, Melgaard B, Askaa J, Oster A, and O'Byrne KJ (2001) Herceptest: HER2 expression and gene amplification in non-small cell lung cancer. Int J Cancer 92:480-483.
46. Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, and Perez CA (1991) N2 (clinical) non-small cell carcinoma of the lung: prospective trials of radiation therapy with total doses 60 Gy by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 20:7-12.
47. Cummings J, Boyd G, Ethell BT, Macpherson JS, Burchell B, Smyth JF, and Jodrell DI (2002a) Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation. Biochem Pharmacol 63:607-613.
48. Cummings J, Boyd G, Macpherson JS, Wolf H, Smith G, Smyth JF, and Jodrell DI (2002b) Factors influencing the cellular accumulation of SN-38 and camptothecin. Cancer Chemother Pharmacol 49:194-200.
49. D'Amico TA, Aloia TA, Moore MB, Herndon JE2nd, Brooks KR, Lau CL and Harpole DH Jr (2000) Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg 69:882-886.
50. Danam RP, Qian XC, Howell SR, and Brent TP (1999) Methylation of selected CpGs in the human O6-methylguanine-DNA methyltransfe-rase promoter region as a marker of gene silencing. Mol Carcinog 24:85-89.
51. Danesi R, De Braud F, Fogli S, Di Paolo A, and Del Tacca M (2001) Pharmacogenetic determinants of anti-cancer drug activity and toxicity. Trends Pharmacol Sci 22:420-426.
52. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, and Starling JJ (1996) Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res 56:4171-4179.
53. Daujat S, Neel H, and Piette J (2001) MDM2: life without p53. Trends Genet 17:459-464.
54. De Braud F, Manzotti M, Fogli S, Danesi R, De Pas T, Giovannetti E, Viale G, and Del Tacca M (2001) Pharmacogenetics of nucleoside metabolizing system in non small cell lung cancer: implication for the chemotherapeutic efficacy of gemcitabine (Abstract 1433). Proc Am Assoc Cancer Res 42:265.
55. De Pas T, De Braud F, Danesi R, Sessa C, Catania C, Curigliano G, Fogli S, Del Tacca M, Zampino G, Sbanotto A, Rocca A, Cinieri S, Marrocco E, Milani A and Goldhirsch A (2000) Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naive patients with advanced non-small-cell lung cancer. Ann Oncol 11:821-827.
56. De Pas T, De Braud F, Mandalà M, Curigliano G, Catania C, Ferretti G, Sozzi P, Solli P and Goldhirsch A (2001) Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. Lung Cancer 31:267-270.
57. Devereux TR, Horikawa I, Anna CH, Annab LA, Afshari CA, and Barrett JC (1999) DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res 59:6087-6090.
58. Di Paolo A, Danesi R, Caputo S, Macchia M, Lastella M, Boggi U, Mosca F, Marchetti A, and Del Tacca M (2001) Inhibition of protein farnesylation enhances the chemotherapeutic efficacy of the novel geranylgeranyltransferase inhibitor BAL9611 in human colon cancer cells. Br J Cancer 84:1535-1543.
59. Dingemans AC, van Ark-Otte J, Span S, Scagliotti GV, van der Valk P, Postmus PE, and Giaccone G (2001) Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer. Lung Cancer 32:117-128.
60. Dingemans AM, van Ark-Otte J, van der Valk P, Apolinario RM, Scheper RJ, Postmus PE, and Giaccone G (1996) Expression of the human major vault protein LRP in human lung cancer samples and normal lung tissues. Ann Oncol 7:625-630.
61. Dingemans AM, Witlox MA, Stallaert RA, van der Valk P, Postmus PE, and Giaccone G (1999) Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res 5:2048-2058.
62. Dosaka-Akita H, Katabami M, Hommura H, Fujioka Y, Katoh H, and Kawakami Y (1999) Bcl-2 expression in non-small cell lung cancers: higher frequency of expression in squamous cell carcinomas with earlier pT status. Oncology 56:259-264.
63. Edelman MJ, Quam H, and Mullins B (2001) Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small cell lung cancer cell lines. Cancer Chemother Pharmacol 48:141-144.
64. Ehrhardt A, Bartels T, Geick A, Klocke R, Paul D, and Halter R (2001) Development of pulmonary bronchiolo-alveolar adenocarcinomas in transgenic mice overexpressing murine c-myc and epidermal growth factor in alveolar type II pneumocytes. Br J Cancer 84:813-818.
65. Eshleman JR, Markowitz SD, Donover PS, Lang EZ, Lutterbaugh JD, Li GM, Longley M, Modrich P, Veigl ML, and Sedwick WD (1996) Diverse hypermutability of multiple expressed sequence motifs present in a cancer with microsatellite instability. Oncogene 12:1425-1432.
66. Esteller M, Hamilton SR, Burger PC, Baylin SB, and Herman JG (1999a) Inactivation of the DNA repair gene O6-methylguanine-DNA methyl-transferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797.
67. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, and Herman JG (1999b) Detection of aberrant promoter hypermethylation of tumor-suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 59:67-70.
68. Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, Issa JP, Sidransky D, Baylin SB and Herman JG (2000) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 60:2368-2371.
69. Evans WE and Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science (Wash DC) 286:487-491.
70. Feld R, Abratt R, Graziano S, Jassem J, Lacquet L, Ninane V, Paesmans M, Rocmans P, Schiepers C, Stahel R, and Stephens R (1997) Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer 17:S3-S10.
71. Felip E and Rosell R (2002) Neoadjuvant chemotherapy in non-small cell lung cancer. Curr Med Chem 9:893-898.
72. Ferreira CG, Span SW, Peters GJ, Kruyt FA, and Giaccone G (2000a) Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460. Cancer Res 60:7133-7141.
73. Ferreira CG, Tolis C, Span SW, Peters GJ, van Lopik T, Kummer AJ, Pinedo HM, and Giaccone G (2000b) Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res 6:203-212.
74. Ferreira R, Naguibneva I, Pritchard LL, Ait-Si-Ali S, and Harel-Bellan A (2001) The Rb/chromatin connection and epigenetic control: opinion. Oncogene 20:3128-3133.
75. Ferreira CG, Huisman C, and Giaccone G (2002) Novel approaches to the treatment of non-small cell lung cancer. Critical Rev Oncol / Hematol 41:57-77.
76. Field JK, Neville EM, Stewart MP, Swift A, Liloglou T, Risk JM, Ross H, Gosney JR, and Donnelly RJ (1996) Fractional allele loss data indicate distinct genetic populations in the development of non-small-cell lung cancer. Br J Cancer 74:1968-1974.
77. Fong KM, Kida Y, Zimmerman PV, Ikenaga M, and Smith PJ (1995a) Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer. Cancer Res 55:4268-4272.
78. Fong KM, Zimmerman PV, and Smith PJ (1995b) Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer. Cancer Res 55:220-223.
79. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Kong WK and Raber M (1995) Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651.
80. Froudarakis ME, Sourvinos G, Fournel P, Bouros D, Vergnon JM, Spandidos DA, and Siafakas NM (1998) Microsatellite instability and loss of heterozygosity at chromosomes 9 and 17 in non-small cell lung cancer. Chest 113:1091-1094.
81. Fujita T, Kiyama M, Tomizawa Y, Kohno T, and Yokota J (1999) Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes. Int J Oncol 15:927-934.
82. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, and Roth JA (1994) Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54:2287-2291.
83. Fukuoka K, Adachi J, Nishio K, Arioka H, Kurokawa H, Fukumoto H, Ishida T, Nomoto T, Yokote H, Tomonari A, Narita N, Yokota J and Saijo N (1997) p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors. Jpn J Cancer Res 88:1009-1016.
84. Fukuoka K, Nishio K, Fukumoto H, Arioka H, Kurokawa H, Ishida T, Iwamoto Y, Tomonari A, Suzuki T, Usuda J, Narita N and Saijo N (2000) Ectopic p16(ink4) expression enhances CPT-11-induced apoptosis through increased delay in S-phase progression in human non-small-cell-lung-cancer cells. Int J Cancer 86:197-203.
85. Gandara DR, Lara PN Jr, Goldberg Z, Roberts P, and Lau DH (2001) Neoadjuvant therapy for non-small cell lung cancer. Anticancer Drugs 12 (Suppl 1):S5-S9.
86. Gasparian AV, Laktionov KK, Belialova MS, Pirogova NA, Tatosyan AG, and Zborovskaya IB (1998) Allelic imbalance and instability of microsatellite loci on chromosome 1p in human non-small-cell lung cancer. Br J Cancer 77:1604-1611.
87. Gasperi-Campani A, Roncuzzi L, Zoli W, Lenzi L, Gruppioni R, Sensi A, Zini N, Farabegoli F and Amadori D (1998) Chromosomal alterations, biological features and in vitro chemosensitivity of SCLC-R1, a new cell line from human metastatic small cell lung carcinoma. Eur J Cancer 34:724-730.
88. Geradts J, Fong KM, Zimmerman PV, Maynard R, and Minna JD (1999) Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities and clinical features in 103 primary non-small cell lung cancers. Clin Cancer Res 5:791-800.
89. Girard L, Zochbauer-Muller S, Virmani AK, Gazdar AF, and Minna JD (2000) Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer and loci clustering. Cancer Res 60:4894-4906.
90. Gorgoulis VG, Mariatos G, Manolis EN, Zacharatos P, Kotsinas A, Liloglou T, Vogiatzi T, Tsagkaraki A, Kokotas S, Tsoli E, Alchanatis M, Sfikakis PP, Asimacopoulos PJ, Field JK and Kittas C (2000) Allelic imbalance at the 5q14 locus is associated with decreased apoptotic rate in non-small cell lung carcinomas (NSCLCs). Possible synergistic effect with p53 gene alterations on apoptosis. Lung Cancer 28:211-224.
91. Gorgoulis VG, Zacharatos P, Kotsinas A, Liloglou T, Kyroudi A, Veslemes M, Rassidakis A, Halazonetis TD, Field JK and Kittas C (1998) Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am J Pathol 153:1749-1765.
92. Grandori C, Cowley SM, James LP, and Eisenman RN (2000) The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16:653-699.
93. Granone P, Margaritora S, D'Andrilli A, Cesario A, Kawamukai K, and Meacci E (2001) Non-small cell lung cancer with single brain metastasis: the role of surgical treatment. Eur J Cardiothorac Surg 20:361-366.
94. Gridelli C, Maione P, Colantuoni G, and Rossi A (2002) Chemotherapy of non-small cell lung cancer in elderly patients. Curr Med Chem 9:1487-1495.
95. Gridelli C, Perrone F, Cigolari S, Manzione L, Piantedosi F, Barbera S, Piazza E, Vinante O, Clerici M, Robbiati F, Bertetto O, Frontini L, Sacco C, Iaffaioli R and Gallo C (2001) The MILES (Multicenter Italian Lung Cancer in the Elderly Study) phase III trial: gemcitabine + vinorelbine vs. vinorelbine and vs. gemcitabine in the elderly advanced NSCLC patients (Abstract 1230). Proc Am Soc Clin Oncol 20:308a.
96. Grim J, D'Amico A, Frizelle S, Zhou J, Kratzke RA, and Curiel DT (1997) Adenovirus-mediated delivery of p16 to pl6-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel. Clin Cancer Res 3:2415-2423.
97. Grompe M, Johnson W, and Jameson JL (1998) Recombinant DNA and genetich techniques, in Principles of Molecular Medicine (Jameson JL ed), pp 9 -24, Humana Press, Totowa.
98. Grossi M, Millward M, Fisher R, Porceddu S, Mac Manus M, Ryan G, Wirth A, and Ball D (2001) Combined modality treatment using concurrent radiotherapy and pharmacologically-guided carboplatin for inoperable and incompletely resected non-small cell lung cancer. Lung Cancer 31:73-82.
99. Haldar S, Basu A, and Croce CM (1997) Bcl2 is the guardian of microtubule integrity. Cancer Res 57:229-233.
100. Heldin C-H and Rönnstrand L (1997) Growth factor receptors in cell transformation, in Oncogenes and tumour suppressors (Peters G and Vousden KH eds) pp 55-85, IRL Press, Oxford.
101. Higashiyama M, Kodama K, Yokouchi H, Takami K, Doi O, Kobayashi H, Tanisaka K and Minamigawa K (1998) Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs. J Surg Oncol 68:19-24.
102. Higashiyama M, Miyoshi Y, Kodama K, Yokouchi H, Takami K, Nishijima M, Nakayama T, Kobayashi H, Minamigawa K, and Nakamura Y (2000) p53regulated GML gene expression in non-small cell lung cancer is a promising relationship to cisplatin chemosensitivity. Eur J Cancer 36:489-495.
103. Hirao T, Nelson HH, Ashok TD, Wain JC, Mark EJ, Christiani DC, Wiencke JK, and Kelsey KT (2001) Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer. Cancer Res 61:612-615.
104. Hoki Y, Fujimori A, and Pommier Y (1997) Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother Pharmacol 40:433-438.
105. Horio Y, Hasegawa Y, Sekido Y, Takahashi M, Roth JA, and Shimokata K (2000) Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells. Cancer Gene Ther 7:537-544.
106. Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK and Houghton JA (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36:393-401.
107. Hu E, Chen Z, Fredrickson T, Zhu Y, Kirkpatrick R, Zhang GF, Johanson K, Sung CM, Liu R, and Winkler J (2000) Cloning and characterization of a novel human class I histone deacetylase that functions as a transcription repressor. J Biol Chem 275:15254-15264.
108. Hutter G and Sinha P (2001) Proteomics for studying cancer cells and the development of chemoresistance. Proteomics 1:1233-1248.
109. Imreh S, Szekely L, Wiman KG, and Klein G (1997) Mechanisms of oncogene perturbation, in Oncogenes and tumour suppressors (Peters G and Vousden KH eds) pp 3-32, IRL Press, Oxford.
110. Inoue A, Narumi K, Matsubara N, Sugawara S, Saijo Y, Satoh K, and Nukiwa T (2000) Administration of wild-type p53 adenoviral vector synergistically enhances the cytotoxicity of anti-cancer drugs in human lung cancer cells irrespective of the status of p53 gene. Cancer Lett 157:105-112.
111. Issaq HJ, Veenstra TD, Conrads TP, and Felschow D (2002) The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 292:587-592.
112. Jemal A, Thomas A, Murray T, and Thun M (2002) Cancer statistics, 2002. CA Cancer J Clin 52:23-47.
113. Jeremic B, Classen J, and Bamberg M (2002) Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer. Int J Radiation Oncology Biol Phys 54:119-130.
114. Johnson JA (2001) Drug target pharmacogenomics. Am J Pharmacogenomics 1:271-281.
115. rd (2002) Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2:76-84.
116. Kalemkerian GP, Jiroutek M, Ettinger DS, Dorighi JA, Johnson DH, and Mabry M (1998) A phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma: an Eastern Cooperative Oncology Group Study. Cancer 83:1102-1108.
117. Kalomenidis I, Orphanidou D, Papamichalis G, Vassilakopoulos T, Skorilas A, Rasidakis A, Papastamatiou H, Jordanoglou J, and Roussos C (2001) Combined expression of p53, Bcl-2 and p21WAF-1 proteins in lung cancer and premalignant lesions: association with clinical characteristics. Lung 179:265-278.
118. Kandioler-Eckersberger D, Kappel S, Mittlbock M, Dekan G, Ludwig C, Janschek E, Pirker R, Wolner E, and Eckersberger F (1999) The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 117:744-750.
119. Kao CH, Hsieh JF, Tsai SC, Ho YJ, Changlai SP, and Lee JK (2001) Paclitaxel-based chemotherapy for non-small cell lung cancer: predicting the response with 99mTctetrofosmin chest imaging. J Nucl Med 42:17-20.
120. Kaufmann SH, Kalemkerian GP, Jasti R, and Mabry M (1995) Effect of v-rasH on sensitivity of NCI-H82 human small cell lung cancer cells to cisplatin, etoposide and camptothecin. Biochem Pharmacol 50:1987-1993.
121. Kavallaris M, Burkhart CA, and Horwitz SB (1999) Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br J Cancer 80:1020-1025.
122. Kim YH, Kim JS, Choi YH, In KH, Park HS, Hong DS, Jeong TJ, Lee YY, Nam E, Lee SN, Lee KS, and Kim HK (2002) Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer. Int J Clin Oncol 7:114-119.
123. Kim CH, Yoo CG, Han SK, Shim YS, and Kim YW (1998a) Genetic instability of microsatellite sequences in non-small cell lung cancers. Lung Cancer 21:21-25.
124. Kim WS, Park C, Hong SK, Park BK, Kim HS, and Park K (2000) Microsatellite instability (MSI) in non-small cell lung cancer (NSCLC) is highly associated with transforming growth factor-beta type II receptor (TGF-βRII) frameshift mutation. Anticancer Res 20:1499-1502.
125. Kim YC, Park KO, Kern JA, Park CS, Lim SC, Jang AS, and Yang JB (1998b) The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer 22:181-190.
126. King TC, Akerley W, Fan AC, Moore T, Mangray S, Hsiu Chen M, and Safran H (2000) p53 mutations do not predict response to paclitaxel in metastatic non-small cell lung carcinoma. Cancer 89:769-773.
127. King TC, Estalilla OC, and Safran H (1999) Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor. Semin Radiat Oncol 9 (Suppl 1):4-11.
128. Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823.
129. Kohno H, Hiroshima K, Toyozaki T, Fujisawa T, and Ohwada H (1999) p53 mutation and allelic loss of chromosome 3p, 9p of preneoplastic lesions in patients with non-small cell lung carcinoma. Cancer 85:341-347.
130. Kohno T, Kawanishi M, Matsuda S, Ichikawa H, Takada M, Ohki M, Yamamoto T, and Yokota J (1998) Homozygous deletion and frequent allelic loss of the 21q11.1-q21.1 region including the ANA gene in human lung carcinoma. Genes Chromosomes Cancer 21:236-243.
131. Komaki R, Milas L, Ro JY, Fujii T, Perkins P, Allen P, Sikes CR, Mountain CF, and Ordonez NG (1998) Prognostic biomarker study in pathologically staged N1 nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 40:787-796.
132. Kotsinas A, Gorgoulis VG, Zacharatos P, Mariatos G, Kokotas S, Liloglou T, Ikonomopoulos J, Zoumpourlis V, Kyroudi A, Field JK, Asimacopoulos PJ and Kittas C (2001) Additional characterization ofa hexanucleotide polymorphic site in the first intron of human H-ras gene: comparative study of its alterations in non-small cell lung carcinomas and sporadic invasive breast carcinomas. Cancer Genet Cytogenet 126:147-154.
133. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Cox J, Krammer B, Gatter KC, and Harris AL (1999) bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. Clin Exp Metastasis 17:545-554.
134. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Whitehouse RM, Talbot DC, Gatter KC, and Harris AL (1997) Potential role of bcl-2 as a suppressor of tumour angiogenesis in non-small-cell lung cancer. Int J Cancer 74:565-570.
135. Kovarova H, Hajduch M, Korinkova G, Halada P, Krupickova S, Gouldsworthy A, Zhelev N and Strnad M (2000) Proteomics approach in classifying the biochemical basis of the anticancer activity of the new olomoucine-derived synthetic cyclin-dependent kinase inhibitor, bohemine. Electrophoresis 21:3757-3764.
136. Kreisholt J, Sorensen M, Jensen PB, Nielsen BS, Andersen CB, and Sehested M (1998) Immunohistochemical detection of DNA topoisomerase IIalpha, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer. Br J Cancer 77:1469-1473.
137. Kroep JR, Giaccone G, Tolis C, Voorn DA, Loves WJ, Groeningen CJ, Pinedo HM, and Peters GJ (2000) Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br J Cancer 83:1069-1076.
138. Kubokura H, Tenjin T, Akiyama H, Koizumi K, Nishimura H, Yamamoto M, and Tanaka S (2001) Relations of the c-myc gene and chromosome 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization. Ann Thorac Cardiovasc Surg 7:197-203.
139. Kumar P, Herndon J 2nd, Langer M, Kohman LJ, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR and Sugarbaker DJ (1996) Patterns of disease failure after trimodality therapy of non-small cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. Cancer 77:2393-2399.
140. Kuramochi M, Fukuhara H, Nobukuni T, Kanbe T, Maruyama T, Ghosh HP, Pletcher M, Isomura M, Onizuka M, Kitamura T, Sekiya T, Reeves RH and Murakami Y (2001) TSLC1 is a tumor-suppressor gene in human non-small cell lung cancer. Nat Genet 27:427-430.
141. La Thangue NB (1997) The retinoblastoma gene product and its relatives, in Oncogenes and tumour suppressors (Peters G and Vousden KH eds) pp 233-259, IRL Press, Oxford, UK.
142. Lai SL, Perng RP, and Hwang J (2000) p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J Biomed Sci 7:64-70.
143. Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, Lara P, Wilder R, Ryu J and Doroshow J (2001) Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. J Clin Oncol 19:442-447.
144. Laudanski J, Niklinska W, Burzykowski T, Chyczewski L, and Niklinski J (2001) Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer. Eur Respir J 17:660-666.
145. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, Lee JH, Han SY, Park JY, Oh RR, Jang JJ, Han JY, Lee JY and Yoo NJ (1999a) Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer 59:5683-5686.
146. Lee YC, Chang YL, Luh SP, Lee JM, and Chen JS (1999b) Significance of P53 and Rb protein expression in surgically treated non-small cell lung cancers. Ann Thorac Surg 68:343-347.
147. Liloglou T, Ross H, Prime W, Donnelly RJ, Spandidos DA, Gosney JR, and Field JK (1997) p53 gene aberrations in non-small-cell lung carcinomas from a smoking population. Br J Cancer 75:1119-1124.
148. Ling YH, Zou Y, and Perez-Soler R (2000) Induction of senescence-like phenotype and loss of paclitaxel sensitivity after wild-type p53 gene transfection of p53-null human non-small cell lung cancer H358 cells. Anticancer Res 20:693-702.
149. Links M, Ribeiro J, Jackson P, Friedlander M, and Russell PJ (1998) Regulation and deregulation of G2 checkpoint proteins with cisplatin. Anticancer Res 18:4057-4066.
150. Liotta LA, Kohn EC, and Petricoin EF (2001) Clinical proteomics - personalized molecular medicine. J Am Med Assoc 286:2211-2214.
151. Liu CX, Musco S, Lisitsina NM, Forgacs E, Minna JD, and Lisitsyn NA (2000) LRP-DIT, a putative endocytic receptor gene, is frequently inactivated in nonsmall cell lung cancer cell lines. Cancer Res 60:1961-1967.
152. Liu WM, Lawrence AJ, and Joel SP (2002) The importance of drug scheduling and recovery phases in determining drug activity. Improving etoposide efficacy in BCR-ABL-positive CML cells. Eur J Cancer 38:842-850.
153. Loeb LA (1994) Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res 54:5059-5063.
154. Loni L, Del Tacca M, and Danesi R (2001) Pharmacogenetics of anticancer drugs in non-Hodgkin lymphomas. Br J Cancer 85:1425-1431.
155. Lopez-Guerrero JA, Bolufer-Gilabert P, Marugan de la Concha I, Barragan-Gonzalez E and Vera-Sempere FJ (1998) Relationship of p53 molecular abnormalities with flow cytometry and growth factor receptor content in lung cancer. Clin Chim Acta 269:63-76.
156. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M, Sanchez JJ, Danenberg KD, Danenberg PV and Rosell R (2002) Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8:2286-2291.
157. Lotfi K, Mansson E, Chandra J, Wang Y, Xu D, Knaust E, Spasokoukotskaja T, Liliemark E, Eriksson S, and Albertioni F (2001) Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide. Br J Haematol 113:339-346.
158. Lu K, Dempsey J, Schultz RM, Shih C, and Teicher BA (2001) Cryptophycin-induced hyperphosphorylation of Bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells. Cancer Chemother Pharmacol 47:170-178.
159. MacDonald SG and McCormick F (1997) The RAS/RAF/ERK signal transduction pathway, in Oncogenes and tumour suppressors (Peters G and Vousden KH eds) pp 121-153, IRL Press, Oxford.
160. Malayeri R, Pirker R, and Huber H (2001) New drugs in the palliative chemotherapy of advanced non-small-cell lung cancer. Onkologie 24:416-421.
161. Manegold C (2001) Chemotherapy for advanced non-small cell lung cancer: standards. Lung Cancer 34 (Suppl 2):S165-S170.
162. Maniwa Y, Yoshimura M, Obayashi C, Inaba M, Kiyooka K, Kanki M, and Okita Y (2001) Association of p53 gene mutation and telomerase activity in resectable non-small cell lung cancer. Chest 120:589-594.
163. Martins SJ and Pereira JR (1999) Clinical factors and prognosis in non-small cell lung cancer. Am J Clin Oncol 22:453-457.
164. Mattern J, Koomagi R, and Volm M (2002) Characteristics of long-term survivors of untreated lung cancer. Lung Cancer 36:277-282.
165. Mattern MR, Hofmann GA, Polsky RM, Funk LR, McCabe FL, and Johnson RK (1993) In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res 5:467-474.
166. Mead LJ, Gillespie MT, Hung JY, Rane US, Rayeroux KC, Irving LB, and Campbell LJ (1997) Frequent loss of heterozygosity in early non-small cell lung cancers at chromosome 9p21 proximal to the CDKN2a gene. Int J Cancer 71:213-217.
167. Mendelsohn LG, Shih C, Chen VJ, Habeck LL, Gates SB, and Shackelford KA (1999) Enzyme inhibition, polyglutamation and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol 26:42-48.
168. Merimsky O, Staroselsky A, Inbar M, Schwartz Y, Wigler N, Mann A, Marmor S, and Greif J (2001) Correlation between c-erbB-4 receptor expression and response to gemcitabine-cisplatin chemotherapy in non-small-cell lung cancer. Ann Oncol 12:1127-1131.
169. Miller VA, Krug LM, Ng KK, Pizzo B, Perez W, Heelan RT, and Kris MG (2000) Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol 18:1346-1350.
170. Miwa M, Eda H, Ura M, Ouchi KF, Keith DD, Foley LH, and Ishitsuka H (1998) High susceptibility ofhuman cancer xenografts with higher levels of cytidine deaminase to a 2′-deoxycytidine antimetabolite, 2′-deoxy-2′-methylidenecytidine. Clin Cancer Res 4:493-497.
171. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, and Reed JC (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805.
172. Mizushima Y, Kashii T, and Kobayashi M (1996) Effect of cisplatin exposure on the degree of N-myc amplification in small cell lung carcinoma cell lines with N-myc amplification. Oncology (Basel) 53:417-421.
173. Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, Gonzalez-Larriba JL, Alberola V, Lorenzo JC, Nunez L, Ro JY, and Martin C (1999) Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17:1786-1793.
174. Murakami Y, Nobukuni T, Tamura K, Maruyama T, Sekiya T, Arai Y, Gomyou H, Tanigami A, Ohki M, Cabin D, Frischmeyer P, Hunt P and Reeves RH (1998) Localization of tumor suppressor activity important in non-small cell lung carcinoma on chromosome 11q. Proc Natl Acad Sci USA 95:8153-8158.
175. Myer MS, Joone G, Chasen MR, and van Rensburg CE (1999) The chemosensitizing potential of GF120918 is independent of the magnitude of P-glycoprotein-mediated resistance to conventional chemotherapeutic agents in a small cell lung cancer line. Oncol Rep 6:217-218.
176. Naaby-Hansen S, Waterfield MD, and Cramer R (2001) Proteomics-post genomic cartography to understand gene function. Trends Pharmacol Sci 22:376-384.
177. Nakatsu S, Kondo S, Kondo Y, Yin D, Peterson JW, Kaakaji R, Morimura T, Kikuchi H, Takeuchi J and Barnett GH (1997) Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11. Cancer Chemother Pharmacol 39:417-423.
178. Narasaki F, Oka M, Fukuda M, Ikeda K, Terashi K, Takatani H, Nakamura T, Soda H, and Kohno S (1997) Multidrug resistance-associated protein gene expression and drug sensitivity in human lung cancer cells. Anticancer Res 17:3493-3497.
179. Nemunaitis J, Swisher SG, Timmons T, Connors D, Mack M, Doerksen L, Weill D, Wait J, Lawrence DD, Kemp BL, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB, Richli WR, Shin DM, Walsh GL, Merritt J and Roth J (2000) Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 18:609-622.
180. Nevins JR (2001) The Rb/E2F pathway and cancer. Hum Mol Genet 10:699-703.
181. NicAmhlaoibh R, Heenan M, Cleary I, Touhey S, O'Loughlin C, Daly C, Nunez G, Scanlon KJ and Clynes M (1999) Altered expression of mRNAs for apoptosismodulating proteins in a low level multidrug resistant variant of a human lung carcinoma cell line that also expresses mdrl mRNA. Int J Cancer 30:368-376.
182. Niki T, Kohno T, Iba S, Moriya Y, Takahashi Y, Saito M, Maeshima A, Yamada T, Matsuno Y, Fukayama M, Yokota J, and Hirohashi S (2002) Frequent colocalization of Cox-2 and laminin-5 gamma2 chain at the invasive front of earlystage lung adenocarcinomas. Am J Pathol 160:1129-1141.
183. Niklinski J, Niklinska W, Chyczewski L, Becker HD, and Pluygers E (2001) Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications. Eur J Cancer Prev 10:213-226.
184. Nishio K, Arioka H, and Saijo N (1997) Apoptosis and chemosensitivity. Gan To Kagaku Ryoho 24:216-221.
185. Nishizaki M, Meyn RE, Levy LB, Atkinson EN, White RA, Roth JA, and Ji L (2001) Synergistic inhibition of human lung cancer cell growth by adenovirus-mediated wild-type p53 gene transfer in combination with docetaxel and radiation therapeutics in vitro and in vivo. Clin Cancer Res 7:2887-2897.
186. Noda N, Matsuzoe D, Konno T, Kawahara K, Yamashita Y, and Shirakusa T (2001) K-ras gene mutations in non-small cell lung cancer in Japanese. Oncol Rep 8:889-892.
187. Non-Small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in nonsmall cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311:899-909.
188. O'Byrne KJ, Cox G, Swinson D, Richardson D, Edwards JG, Lolljee J, Andi A, Koukourakis MI, Giatromanolaki A, Gatter K, Harris AL, Waller D and Jones JL (2001) Towards a biological staging model for operable non-small cell lung cancer. Lung Cancer 34 (Suppl 2):S83-S89.
189. Ohmori T, Podack ER, Nishio K, Takahashi M, Miyahara Y, Takeda Y, Kubota N, Funayama Y, Ogasawara H, Ohira T, Ohta S, and Saijo N (1993) Apoptosis oflung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 192:30-36.
190. Ohsaki Y, Tanno S, Fujita Y, Toyoshima E, Fujiuchi S, Nishigaki Y, Ishida S, Nagase A, Miyokawa N, Hirata S and Kikuchi K (2000) Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 7:603-607.
191. Oka M, Fukuda M, Sakamoto A, Takatani H, Fukuda M, Soda H, and Kohno S (1997) The clinical role of MDR1 gene expression in human lung cancer. Anticancer Res 17:721-724.
192. Okami K, Wu L, Riggins G, Cairns P, Goggins M, Evron E, Halachmi N, Ahrendt SA, Reed AL, Hilgers W, Kern SE, Koch WM, Sidransky D and Jen J (1998) Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res 58:509-511.
193. Osada H, Tatematsu Y, Masuda A, Saito T, Sugiyama M, Yanagisawa K, and Takahashi T (2001) Heterogeneous transforming growth factor (TGF)-β unresponsiveness and loss of TGF-β receptor type II expression caused by histone deacetylation in lung cancer cell lines. Cancer Res 61:8331-8339.
194. Osaki S, Nakanishi Y, Takayama K, Pei XH, Ueno H, and Hara N (2000) Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wildtype p53 gene in human lung cancer cells. Cancer Gene Ther 7:300-307.
195. Osaki T, Oyama T, Gu CD, Yamashita T, So T, Takenoyama M, Sugio K, and Yasumoto K (2002) Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small-cell lung cancer. J Clin Oncol 20:2930-2936.
196. Oshika Y, Nakamura M, Tokunaga T, Fukushima Y, Abe Y, Ozeki Y, Yamazaki H, Tamaoki N, and Ueyama Y (1998) Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer. Mod Pathol 11:1059-1063.
197. Oshita F, Nishio K, Kameda Y, Mitsuda A, Ikehara M, Tanaka G, Yamada K, Nomura I, Noda K, Arai H, Ito H, and Nakayama H (2000) Increased expression levels of p53 correlate with good response to cisplatin-based chemotherapy in non-small cell lung cancer. Oncol Rep 7:1225-1228.
198. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P, and Klastersky J (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1, 052 patients. The European Lung Cancer Working Party. J Clin Oncol 13:1221-1230.
199. Pantel K, Izbicki J, Passlick B, Angstwurm M, Haussinger K, Thetter O, and Riethmuller G (1996) Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases. Lancet 347:649-653.
200. Park JY, Jeon HS, Park SH, Park TI, Son JW, Kim CH, Park JH, Kim IS, Jung TH, and Jun SH (2000) Microsatellite alteration in histologically normal lung tissue of patients with non-small cell lung cancer. Lung Cancer 30:83-89.
201. Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, Buyse M, Menard S, Pierotti M, and Rilke F (1997) Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15:2858-2865.
202. Perez-Soler R, Kemp B, Wu QP, Mao L, Gomez J, Zeleniuch-Jacquotte A, Yee H, Lee JS, Jagirdar J, and Ling YH (2000) Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 6:4932-4938.
203. Perrais M, Pigny P, Copin MC, Aubert JP, and Van Seuningen I (2002) Induction of MUC2 and MUC5AC mucins by factors of the Epidermal Growth Factor (EGF) family is mediated by EGF reeeptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1*. J Biol Chem 277:32258-32267.
204. Picard E, Seguin C, Monhoven N, Rochette-Egly C, Siat J, Borrelly J, Martinet Y, Martinet N, and Vignaud JM (1999) Expression of retinoid receptor genes and proteins in non-small-cell lung cancer. J Natl Cancer Inst 91:1059-1066.
205. Pines J (1997) Mammalian cell cycle control, in Oncogenes and tumour suppressors (Peters G and Vousden KH eds) pp 189-232, IRL Press, Oxford.
206. Pitz CC, Maas KW, Van Swieten HA, de la Riviere AB, Hofman P and Schramel FM (2002) Surgery as part of combined modality treatment in stage IIIB non-small cell lung cancer. Ann Thorac Surg 74:164-169.
207. Pletcher MT, Nobukuni T, Fukuhara H, Kuramochi M, Maruyama T, Sekiya T, Sussan T, Isomura M, Murakami Y and Reeves RH (2001) Identification of tumor suppressor candidate genes by physical and sequence mapping of the TSLC1 region of human chromosome 11q23. Gene 273:181-189.
208. Poirier F, Pontet M, Labas V, le Caer JP, Sghiouar-Imam N, Raphael M, Caron M, and Joubert-Caron R (2001) Two-dimensional database of a Burkitt lymphoma cell line (DG 75) proteins: protein pattern changes following treatment with 5′-azycytidine. Electrophoresis 22:1867-1877.
209. Poland J, Schadendorf D, Lage H, Schnolzer M, Celis JE, and Sinha P (2002) Study of therapy resistance in cancer cells with functional proteome analysis. Clin Chem Lab Med 40:221-234.
210. Pommier Y, Pourquier P, Urasaki Y, Wu J, and Laco GS (1999) Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resistance Update 2:307-318.
211. PORT Meta-analysis Trialists Group (1998) Postoperative radiotherapy in non-small cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomized controlled trials. Lancet 352:257-263.
212. Pottgen C, Eberhardt W, Bildat S, Stuben G, Stamatis G, Hillejan L, Sohrab S, Teschler H, Seeber S, Sack H, and Stuschke M (2002) Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb:) a pilot phase I/II trial. Ann Oncol 13:403-411.
213. Prakash S, Foster BJ, Meyer M, Wozniak A, Heilbrun LK, Flaherty L, Zalupski M, Radulovic L, Valdivieso M, and Lo Russo PM (2001) Chronic oral administration of CI-994: a phase I study. Invest New Drugs 19:1-11.
214. Pylkkanen L, Karjalainen A, Anttila S, Vainio H, and Husgafvel-Pursiainen K (1997) No evidence of microsatellite instability but frequent loss of heterozygosity in primary resected lung cancer. Environ Mol Mutagen 30:217-223.
215. Qian XC and Brent TP (1997) Methylation hot spots in the 5′-flanking region denote silencing of the O6-methylguanine-DNA methyltrans-ferase gene. Cancer Res 57:3672-3677.
216. Ramakrishna G, Sithanandam G, Cheng RY, Fornwald LW, Smith GT, Diwan BA, and Anderson LM (2000) K-ras p21 expression and activity in lung and lung tumors. Exp Lung Res 26:659-671.
217. Reinmuth N, Brandt B, Kunze WP, Junker K, Thomas M, Achatzy R, Scheld HH, and Semik M (2000) Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur Respir J 16:991-996.
218. Reissmann PT, Koga H, Figlin RA, Holmes EC, and Slamon DJ (1999) Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group. J Cancer Res Clin Oncol 125:61-70.
219. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, and Marks PA (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95:3003-3007.
220. Rinaldi M and Crinò L (2001) Induction chemotherapy with gemeitabine and cisplatin in stage III non-small cell lung cancer. Lung Cancer 34 (Suppl 4):S25-S30.
221. Robson C, Wright KA, Twentyman PR, Lambert PA, and Griffin RJ (1998) Chem synthesis and biological properties of novel fluorescent antifolates in Pgp- and MRP-overexpressing tumour cell lines. Biochem Pharmacol 56:807-816.
222. Rodenhuis S, Boerrigter L, Top B, Slebos RJ, Mooi WJ, van't Veer L and van Zandwijk N (1997) Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol 15:285-291.
223. Rodriguez J, Pawel J, Pluzanska A, Gorbounova V, Fossella F, Kaukel E, Mattson K, Millward M, Kim YS, Gamza F, Berille J and Belani CP (2001) A multicenter, randomized phase III study of docetaxel + cisplatin (DC) and docetaxel + carboplatin (DCB)vs. vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advanced and metastatic non-small cell lung cancer (Abstract 1252). Proc Am Soc Clin Oncol 20:314a.
224. Rom WN, Hay JG, Lee TC, Jiang Y, and Tchou-Wong K-M (2000) Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med 161:1355-1367.
225. Rosell R and Felip E (2001) Predicting response to paclitaxel/carboplatin-based therapy in non-small cell lung cancer. Semin Oncol 28 (Suppl 14):37-44.
226. Rosell R, Gómez-Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J, Olazabal A, Canela M, Ariza A, Skacel Z, Morera-Prat J and Abad A (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 330:153-158.
227. Rosell R, Green M, and Gumerlock P (2001) Adv in the treatment of non-small cell lung cancer: molecular markers take the stage. Semin Oncol 28 (Suppl 2):28-34.
228. Rosell R, Molina F, Moreno I, Martinez E, Pifarre A, Font A, Li S, Skacel Z, Gomez-Codina J, Camps C, Monzó M and de Anta JM (1995) Mutated K-ras gene analysis in a randomized trial of preoperative chemotherapy plus surgery versus surgery in stage IIIA non-small cell lung cancer. Lung Cancer 12 (Suppl 1):S59-S70.
229. Rosell R, Monzo M, Pifarre A, Ariza A, Sanchez JJ, Moreno I, Maurel J, Lopez MP, Abad A, and de Anta JM (1996) Molecular staging of non-small cell lung cancer according to K-ras genotypes. Clin Cancer Res 2:1083-1086.
230. Rosell R, Pifarre A, Monzo M, Astudillo J, Lopez-Cabrerizo MP, Calvo R, Moreno I, Sanchez-Cespedes M, Font A, and Navas-Palacios JJ (1997) Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors. Int J Cancer 74:330-334.
231. Roses AD (2000) Pharmacogenetics and the practice of medicine. Nature (Lond) 405:857-865.
232. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Lee JS, Dhingra H, De Caro L, Chasen M, and McGavran M (1994) A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86:673-680.
233. Roth JA, Swisher SG, and Meyn RE (1999) p53 tumor suppressor gene therapy for cancer. Oncology (Huntingt) 13 (Suppl 5):148-154.
234. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M, and Dmitrovsky E (1995) Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55:5038-5042.
235. Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B and Iglesias J (1999) Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:1194-1198.
236. Safran H, King T, Choy H, Gollerkeri A, Kwakwa H, Lopez F, Cole B, Myers J, Tarpey J, and Rosmarin A (1996) p53 mutations do not predict response to paclitaxel/radiation for non-small cell lung carcinoma. Cancer 78:1203-1210.
237. Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, and Nakanishi O (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 96:4592-4597.
238. Salgia R and Skarin AT (1998) Molecular abnormalities in lung cancer. J Clin Oncol 16:1207-1217.
239. Samid D, Hudgins WR, Shack S, Liu L, Prasanna P, and Myers CE (1997) Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv Exp Med Biol 400A:501-505.
240. Sanchez-Cespedes M, Decker PA, Doffek KM, Esteller M, Westra WH, Alawi EA, Herman JG, Demeure MJ, Sidransky D, and Ahrendt SA (2001) Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. Cancer Res 61:2092-2096.
241. Sanchez-Cespedes M, Reed AL, Buta M, Wu L, Westra WH, Herman JG, Yang SC, Jen J, and Sidransky D (1999) Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene 18:5843-5849.
242. Sanchez-Cespedes M, Rosell R, Pifarre A, Lopez-Cabrerizo MP, Barnadas A, Sanchez JJ, Lorenzo JC, Abad A, Monzo M, and Navas-Palacios JJ (1997) Microsatellite alterations at 5q21, 11p13 and 11p15.5 do not predict survival in non-small cell lung cancer. Clin Cancer Res 3:1229-1235.
243. Sartorius UA and Krammer PH (2002) Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97:584-592.
244. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Bianco A, Boni C, Marangolo M, Failla G, Adamo V, Altavilla G, Ceribelli A, Clerici M, Di Costanzo F, Frontini L and Tonato M (2001) Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer (Abstract 1227). Proc Am Soc Clin Oncol 20:308a.
245. Scheffer GL, Schroeijers AB, Izquierdo MA, Wiemer EA, and Scheper RJ (2000) Lung resistance-related protein/major vault protein and vaults in multidrug-resistant cancer. Curr Opin Oncol 12:550-556.
246. Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ, Laufman L, Gralla R, Kuball J, Buhl R, Heussel CP, Kommoss F, Perruchoud AP, Shepherd FA, Fritz MA, Horowitz JA, Huber C and Rochlitz C (2001) Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 19:1750-1758.
247. Sekido Y, Fong KM, and Minna JD (1998) Progress in understanding the molecular pathogenesis of of human lung cancer. Biochin Biophys Acta 1978:F21-F59.
248. Sekine I, Takami S, Guang SG, Yokose T, Kodama T, Nishiwaki Y, Kinoshita M, Matsumoto H, Ogura T, and Nagai K (1998) Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer. Oncol Rep 5:351-354.
249. Shackney SE and Shankey TV (1997) Common patterns of genetic evolution in human solid tumors. Cytometry 29:1-27.
250. 1 arrest checkpoint in response to DNA damage. Mol Cell Biol 18:378-387.
251. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ, and Rollins BJ (1995) Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 55:505-509.
252. Sherbet GW and Lakshmi MS (1997) The genetics of cancer. Academic press, San Diego.
253. Shiau YC, Tsai SC, Wang JJ, Ho YJ, Ho ST, and Kao CH (2001) Technetium-99m tetrofosmin chest imaging related to p-glycoprotein expression for predicting the response with paclitaxel-based chemotherapy for non-small cell lung cancer. Lung 179:197-207.
254. Shimizu E, Coxon A, Otterson GA, Steinberg SM, Kratzke RA, Kim YW, Fedorko J, Oie H, Johnson BE and Mulshine JL (1994) RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma and mesothelioma. Oncogene 9:2441-2448.
255. Shiseki M, Kohno T, Adachi J, Okazaki T, Otsuka T, Mizoguchi H, Noguchi M, Hirohashi S, and Yokota J (1996) Comparative allelotype of early and advanced stage non-small cell lung carcinomas. Genes Chromosomes Cancer 17:71-77.
256. Shiseki M, Kohno T, Nishikawa R, Sameshima Y, Mizoguchi H, and Yokota J (1994) Frequent allelic losses on chromosomes 2q, 18q and 22q in advanced non-small cell lung carcinoma. Cancer Res 54:5643-5648.
257. Shivapurkar N, Virmani AK, Wistuba II, Milchgrub S, Mackay B, Minna JD, and Gazdar AF (1999) Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res 5:17-23.
258. Shriver SP, Shriver MD, Tirpak DL, Bloch LM, Hunt JD, Ferrell RE and Siegfried JM (1998) Trinucleotide repeat length variation in the human ribosomal protein L14 gene (RPL14): localization to 3p21.3 and loss of heterozygosity in lung and oral cancers. Mutat Res 406:9-23.
259. Sigal A and Rotter V (2000) Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60:6788-6793.
260. Singhal RL, Yeh YA, Szekeres T, and Weber G (1992) Increased deoxycytidine kinase activity in cancer cells and inhibition by difluorodeoxycytidine. Oncol Res 4:517-522.
261. Sloviter RS (2002) Apoptosis: a guide for the perplexed. Trends Pharmacol Sci 23:19-24.
262. Socinski MA, Schell MJ, Peterman A, Bakri K, Yates S, Gitten R, Unger P, Lee J, Lee JH, Tynan M, Moore M, and Kies MS (2002) Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20:1335-1343.
263. Souquet PJ and Geriniere L (2001) The role of chemotherapy in early stage of non-small cell lung cancer. Lung Cancer 34 (Suppl 2):S155-S158.
264. Spanakis NE, Gorgoulis V, Mariatos G, Zacharatos P, Kotsinas A, Garinis G, Trigidou R, Karameris A, Tsimara-Papastamatiou H, Kouloukousa M, Manolis EN and Kittas C (1999) Aberrant p16 expression is correlated with hemizygous deletions at the 9p21-22 chromosome region in non-small cell lung carcinomas. Anticancer Res 19:1893-1899.
265. Sugio K, Tsukamoto S, Ushijima C, Yamazaki K, Kase S, Yamaguchi M, Ondo K, Yano T, and Sugimachi K (2001) Clinical significance of the Rb expression in adenocarcinoma of the lung. Anticancer Res 21:1931-1935.
266. 1 checkpoint function as determinants of resistance of human lung cancer cells against the antisignaling drug UCN-01 (7-Hydroxystaurosporine). Cancer Res 59:4406-4412.
267. Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RD, Hamilton AD, and Sebti SM (1999) Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, taxol and gemcitabine. Cancer Res 59:4919-4926.
268. Suzuki K, Ogura T, Yokose T, Sekine I, Nagai K, Kodama T, Mukai K, Nishiwaki Y, and Esumi H (1998) Microsatellite instability in female non-small-cell lung cancer patients with familial clustering of malignancy. Br J Cancer 77:1003-1008.
269. Taguchi T, Cheng GZ, Bell DW, Balsara B, Liu Z, Siegfried JM, and Testa JR (1997) Combined chromosome microdissection and comparative genomic hybridization detect multiple sites of amplification DNA in a human lung carcinoma cell line. Genes Chromosomes Cancer 20:208-212.
270. Tan B, Piwnica-Worms D, and Ratner L (2000) Multidrug resistance transporters and modulation. Curr Opin Oncol 12:450-458.
271. Tan S, Seow TK, Liang RC, Koh S, Lee CP, Chung MC, and Hooi SC (2002) Proteome analysis of butyrate-treated human colon cancer cells (HT-29). Int J Cancer 98:523-531.
272. Tang X, Khuri FR, Lee JJ, Kemp BL, Liu D, Hong WK, and Mao L (2000) Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small cell lung cancer. J Natl Cancer Inst 92:1511-1516.
273. Tani M, Takenoshita S, Kohno T, Hagiwara K, Nagamachi Y, Harris CC, and Yokota J (1997) Infrequent mutations of the transforming growth factor beta-type II receptor gene at chromosome 3p22 in human lung cancers with chromosome 3p deletions. Carcinogenesis 18:1119-1121.
274. 2/M-phase anticancer drugs in human tumor-derived cell lines. Invest New Drugs 18:139-147.
275. 2/M transition by p53. Oncogene 20:1803-1815.
276. Thiberville L, Bourguignon J, Metayer J, Bost F, Diarra-Mehrpour M, Bignon J, Lam S, Martin JP, and Nouvet G (1995) Frequency and prognostic evaluation of 3p21-22 allelic losses in non-small-cell lung cancer. Int J Cancer 64:371-377.
277. Thomas M, Rube C, Semik M, von Eiff M, Freitag L, Macha HN, Wagner W, Klinke F, Scheld HH, Willich N, Berdel WE and Junker K (1999) Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol 17:1185-1188.
278. Tolis C, Peters GJ, Ferreira CG, Pinedo HM, and Giaccone G (1999) Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 35:796-807.
279. Tomizawa Y, Adachi J, Kohno T, Hamada K, Saito R, Noguchi M, Matsuno Y, Hirohashi S, Yamaguchi N, and Yokota J (1999) Prognostic significance of allelic imbalances on chromosome 9p in stage I non-small cell lung carcinoma. Clin Cancer Res 5:1139-1146.
280. Tran Y, Benbatoul K, Gorse K, Rempel S, Futreal A, Green M, and Newsham I (1998) Novel regions of allelic deletion on chromosome 18p in tumors of the lung, brain and breast. Oncogene 17:3499-3505.
281. Tran YK and Newsham IF (1996) High-density marker analysis of 11p15.5 in non-small cell lung carcinomas reveals allelic deletion of one shared and one distinct region when compared to breast carcinomas. Cancer Res 56:2916-2921.
282. Trussardi A, Poitevin G, Gorisse MC, Faroux MJ, Bobichon H, Delvincourt C, and Jardillier JC (1998) Sequential overexpression of LRP and MRP but not P-gp 170 in VP16-selected A549 adenocarcinoma cells. Int J Oncol 13:543-548.
283. Tsai CM, Chang KT, Chen JY, Chen YM, Chen MH, and Perng RP (1996a) Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu. Cancer Res 56:794-801.
284. Tsai CM, Chang KT, Li L, Perng RP, and Yang LY (2000) Inter-relationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression and epidermal growth factor receptor level in non-small cell lung cancer cells. Jpn J Cancer Res 91:213-222.
285. Tsai CM, Chang KT, Perng RP, Mitsudomi T, Chen MH, Kadoyama C, and Gazdar AF (1993) Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst 85:897-901.
286. Tsai CM, Chang KT, Wu LH, Chen JY, Gazdar AF, Mitsudomi T, Chen MH, and Perng RP (1996b) Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 56:206-209.
287. Tsai CM, Levitzki A, Wu LH, Chang KT, Cheng CC, Gazit A, and Perng RP (1996c) Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res 56:1068-1074.
288. Tseng JE, Kemp BL, Khuri FR, Kurie JM, Lee JS, Zhou X, Liu D, Hong WK, and Mao L (1999) Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers. Cancer Res 59:4798-4803.
289. Tsurutani J, Komiya T, Uejima H, Tada H, Syunichi N, Oka M, Kohno S, Fukuoka M, and Nakagawa K (2002) Mutational analysis of the beta-tubulin gene in lung cancer. Lung Cancer 35:11-16.
290. Urasaki Y, Laco GS, Pourquier P, Takebayashi Y, Kohlhagen G, Gioffre C, Zhang H, Chatterjee D, Pantazis P, and Pommier Y (2001) Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line. Cancer Res 61:1964-1969.
291. van Bree C, Kreder N, Loves W, Franken N, Peters G, and Haveman J (2002) Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines. Int J Radiat Oncol Biol Phys 54:237-244.
292. Van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, Bartelink H, and Begg AC (2000) DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 89:160-166.
293. Van Meerbeeck JP, Smit EF, Lianes P, Schramel F, Lenz M, Debruyne C, and Giaccone G (2001) A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) (Abstract 1228). Proc Am Soc Clin Oncol 20:308a.
294. Van Waardenburg RC, Meijer C, Burger H, Nooter K, De Vries EG, Mulder NH, and De Jong S (1997) Effects of an inducible anti-sense c-myc gene transfer in a drug-resistant human small-cell-lung-carcinoma cell line. Int J Cancer 73:544-550.
295. Van Waardenburg RC, Prins J, Meijer C, Uges DR, De Vries EG, and Mulder NH (1996) Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines. Anticancer Res 16:1963-1970.
296. Varella-Garcia M, Gemmill RM, Rabenhorst SH, Lotto A, Drabkin HA, Archer PA, and Franklin WA (1998) Chromosomal duplication accompanies allelic loss in non-small cell lung carcinoma. Cancer Res 58:4701-4707.
297. Vastag B (2000) Detection network gives early cancer tests a push. J Natl Cancer Inst 92:786-788.
298. Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, Tonk V, Minna JD, and Gazdar AF (1998) Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 21:308-319.
299. Virmani AK, Rathi A, Sathyanarayana UG, Padar A, Huang CX, Cunnigham HT, Farinas AJ, Milchgrub S, Euhus DM, Gilcrease M, Herman J, Minna JD and Gazdar AF (2001a) Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter 1A in breast and lung carcinomas. Clin Cancer Res 7:1998-2004.
300. Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD, and Gazdar AF (2001b) Promoter methylation and silencing of the retinoic acid receptor beta gene in lung carcinomas. J Natl Cancer Inst 92:1303-1307.
301. Vogt U, Zaczek A, Klinke F, Granetzny A, Bielawski K, and Falkiewicz B (2002) p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer. J Cancer Res Clin Oncol 128:141-147.
302. Volm M, Efferth T, and Mattern J (1992) Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res 12:11-20.
303. Volm M, Koomagi R, Mattern J, and Efferth T (2002) Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients. Clin Cancer Res 8:1843-1848.
304. Wang J, Liu X, and Jiang W (2000) Expression of LRP, MRP and MDR1 in nonsmall-cell lung cancer and its clinical significance. Zhonghua Zhong Liu Za Zhi 22:304-307.
305. Wang LG, Liu XM, Kreis W, and Budman DR (1999) The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44:355-361.
306. Wasinger VC and Corthals GL (2002) Proteomic tools for biomedicine. J Chromatogr B Analyt Technol Biomed Life Sci 771:33-48.
307. Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS and Futscher BW (1997) Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol 17:5612-5619.
308. Werner-Wasik M, Scott C, Cox JD, Sause WT, Byhardt RW, Asbell S, Russell A, Komaki R, and Lee JS (2000) Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48:1475-1482.
309. Whitelegge JP and Le Coutre J (2001) Proteomics - Making sense of genomic information for drug discovery. Am J Pharmacogenomics 1:29-35.
310. Wistuba II, Gazdar AF, and Minna JD (2001) Molecular genetics of small cell lung carcinoma. Semin Oncol 28 (Suppl 4):3-13.
311. 6-Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res 61:8113-8117.
312. INK4a Lesions are common, early abnormalities that undergo clonal expansion in Barret's metaplastic epithelium. Cancer Res 61:8284-8289.
313. Wright SR, Boag AH, Valdimarsson G, Hipfner DR, Campling BG, Cole SP, and Deeley RG (1998) Immunohistochemical detection of multidrug resistance protein in human lung cancer and normal lung. Clin Cancer Res 4:2279-2289.
314. Wu W, Fan YH, Kemp BL, Walsh G, and Mao L (1998) Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res 58:4082-4085.
315. Xu L, Chow J, Bonacum J, Eisenberger C, Ahrendt SA, Spafford M, Wu L, Lee SM, Piantadosi S, Tockman MS, Sidransky D, and Jen J (2001) Microsatellite instability at AAAG repeat sequences in respiratory tract cancers. Int J Cancer 91:200-204.
316. Yamamoto Y, Shimizu E, Masuda N, Takada M, and Sone S (1998) RB protein status and chemosensitivity in non-small cell lung cancers. Oncol Rep 5:447-451.
317. Yoon SS, Ahn KS, Kim SH, Shim YM, and Kim J (2001) In vitro establishment of cis-diammine-dichloroplatinum(II) resistant lung cancer cell line and modulation of apoptotic gene expression as a mechanism of resistant phenotype. Lung Cancer 33:221-228.
318. You XL, Yen L, Zeng-Rong N, Al Moustafa AE, and Alaoui-Jamali MA (1998) Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells. Oncogene 17:3177-3186.
319. Young LC, Campling BG, Cole SP, Deeley RG, and Gerlach JH (2001) Multidrug resistance proteins MRP3, MRP1 and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res 7:1798-1804.
320. Young LC, Campling BG, Voskoglou-Nomikos T, Cole SP, Deeley RG, and Gerlach JH (1999) Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin Cancer Res 5:673-680.
321. Zhang L and Hung MC (1996) Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin. Oncogene 12:571-576.
322. Waf1/Cip1 acts in synergy with bcl-2 to confer multidrug resistance in a camptothecin-selected human lung-cancer cell line. Int J Cancer 83:790-797.
323. Zhou X, Kemp BL, Khuri FR, Liu D, Lee JJ, Wu W, Hong WK, and Mao L (2000) Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. Clin Cancer Res 6:559-565.
324. Zhu WG, Dai Z, Ding H, Srinivasan K, Hall J, Duan W, Villalona-Calero MA, Plass C, and Otterson GA (2001a) Increased expression of unmethylated CDKN2D by 5-aza-2′-deoxycytidine in human lung cancer cells. Oncogene 20:7787-7796.
325. Zhu WG, Lakshmanan RR, Beal MD, and Otterson GA (2001b) DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors, Cancer Res 61:1327-1333.
326. Zienolddiny S, Ryberg D, Arab MO, Skaug V, and Haugen A (2001) Loss of heterozygosity is related to p53 mutations and smoking in lung cancer. Br J Cancer 84:226-231.
327. Zoli W, Ricotti L, Dal Susino M, Barzanti F, Frassineti GL, Folli S, Tesei A, Bacci F, and Amadori D (1999) Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer. Br J Cancer 81:609-615.